EHEALTH, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, unaudited) June 30, 2026 December 31, 2025 Assets Current assets: Cash and cash equivalents $ 69,681 $ 73,725 Short-term marketable securities 31,367 3,495 Accounts receivable 1,818 7,688 Contract assets – commissions receivable – current 202,804 236,116 Prepaid expenses and other current assets 10,083 13,328 Total current assets 315,753 334,352 Contract assets – commissions receivable – non-current 804,806 886,614 Property and equipment, net 4,105 4,531 Operating lease right-of-use assets 6,915 8,429 Restricted cash 2,630 3,090 Other assets 23,823 25,452 Total assets $ 1,158,032 $ 1,262,468 Liabilities, convertible preferred stock and stockholders’ equity Current liabilities: Accounts payable $ 2,953 $ 28,323 Accrued compensation and benefits 14,878 41,009 Accrued marketing expenses 2,779 16,182 Lease liabilities – current 6,615 7,349 Other current liabilities 4,524 6,207 Total current liabilities 31,749 99,070 Long-term debt 114,608 112,954 Deferred income taxes – non-current 48,566 57,223 Lease liabilities – non-current 10,950 14,050 Other non-current liabilities 5,073 5,519 Total liabilities 210,946 288,816 Commitments and contingencies (Note 8) Convertible preferred stock 406,283 382,057 Stockholders’ equity: Common stock 46 44 Additional paid-in capital 752,110 761,495 Treasury stock, at cost (199,998) (199,998) Retained earnings (deficit) (11,586) 30,116 Accumulated other comprehensive income (loss) 231 (62) Total stockholders’ equity 540,803 591,595 Total liabilities, convertible preferred stock and stockholders’ equity $ 1,158,032 $ 1,262,468 The accompanying notes are an integral part of these condensed consolidated financial statements. 2 Table of Contents EHEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (in thousands, except per share amounts, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Revenue: Commission $ 29,804 $ 54,731 $ 109,611 $ 153,677 Other 3,762 6,051 11,973 20,224 Total revenue 33,566 60,782 121,584 173,901 Operating costs and expenses: Marketing and advertising 11,781 21,425 37,174 62,614 Customer care and enrollment 22,298 27,910 54,582 65,131 Technology and content 11,301 11,354 22,636 23,955 General and administrative 15,583 21,582 31,095 38,892 Impairment, restructuring and other charges 60 1,555 6,432 1,555 Total operating costs and expenses 61,023 83,826 151,919 192,147 Loss from operations (27,457) (23,044) (30,335) (18,246) Interest expense (4,054) (2,348) (8,089) (4,996) Other income, net 832 1,340 1,672 2,916 Loss before income taxes (30,679) (24,052) (36,752) (20,326) Benefit from income taxes (7,084) (6,654) (8,443) (4,878) Net loss (23,595) (17,398) (28,309) (15,448) Preferred stock dividends (6,201) (5,846) (12,334) (11,627) Change in preferred stock redemption value (7,715) (6,539) (14,975) (12,680) Net loss attributable to common stockholders $ (37,511) $ (29,783) $ (55,618) $ (39,755) Net loss per share attributable to common stockholders: Basic and diluted $ (1.18) $ (0.98) $ (1.77) $ (1.32) Weighted-average number of shares used in per share amounts: Basic and diluted 31,780 30,404 31,458 30,202 Comprehensive loss: Net loss $ (23,595) $ (17,398) $ (28,309) $ (15,448) Unrealized gain (loss) on available for sale debt securities, net of tax (3) 9 (30) (28) Foreign currency translation adjustments 176 (4) 323 2 Comprehensive loss $ (23,422) $ (17,393) $ (28,016) $ (15,474) The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Table of Contents EHEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (in thousands, unaudited) Common Stock Additional Paid-in Capital Treasury Stock Retained Earnings (Accumulated Deficit) Accumulated Other Comprehensive Income (Loss) Total Stockholders’ Equity Shares Amount Shares Amount Balance as of December 31, 2025 44,797 $ 44 $ 761,495 13,803 $ (199,998) $ 30,116 $ (62) $ 591,595 Issuance of common stock in connection with equity incentive plans 203 1 — — — — — 1 Repurchase of shares to satisfy employee tax withholding obligations — — (161) 45 — — — (161) Dividends and accretion related to convertible preferred stock — — — — — (13,393) — (13,393) Stock-based compensation — — 2,283 — — — 2,283 Other comprehensive income, net of tax — — — — — — 120 120 Net loss — — — — — (4,714) — (4,714) Balance as of March 31, 2026 45,000 $ 45 $ 763,617 13,848 $ (199,998) $ 12,009 $ 58 $ 575,731 Issuance of common stock in connection with equity incentive plans 763 1 — — — — — 1 Repurchase of shares to satisfy employee tax withholding obligations — — (49) 30 — — — (49) Dividends and accretion related to convertible preferred stock — — (13,916) — — — — (13,916) Issuance of common stock for employee stock purchase program 64 — 102 — — — — 102 Stock-based compensation — — 2,356 — — — 2,356 Other comprehensive income, net of tax — — — — — — 173 173 Net loss — — — — — (23,595) — (23,595) Balance as of June 30, 2026 45,827 $ 46 $ 752,110 13,878 $ (199,998) $ (11,586) $ 231 $ 540,803 The accompanying notes are an integral part of these condensed consolidated financial statements. 4 Table of Contents EHEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (in thousands, unaudited) Common Stock Additional Paid-in Capital Treasury Stock Retained Earnings (Accumulated Deficit) Accumulated Other Comprehensive Loss Total Stockholders’ Equity Shares Amount Shares Amount Balance as of December 31, 2024 43,225 $ 43 $ 773,371 13,379 $ (199,998) $ 15,246 $ (234) $ 588,428 Issuance of common stock in connection with equity incentive plans 252 — — — — — — — Repurchase of shares to satisfy employee tax withholding obligations — — (699) 75 — — — (699) Dividends and accretion related to convertible preferred stock — — — — — (11,922) — (11,922) Stock-based compensation — — 3,897 — — — 3,897 Other comprehensive loss, net of tax — — — — — — (31) (31) Net income — — — — — 1,950 — 1,950 Balance as of March 31, 2025 43,477 $ 43 $ 776,569 13,454 $ (199,998) $ 5,274 $ (265) $ 581,623 Issuance of common stock in connection with equity incentive plans 617 1 — — — — — 1 Repurchase of shares to satisfy employee tax withholding obligations — — (1,128) 196 — — — (1,128) Dividends and accretion related to convertible preferred stock — — (12,385) — — — — (12,385) Issuance of common stock for employee stock purchase program 43 — 189 — — — — 189 Stock-based compensation — — 4,016 — — — — 4,016 Other comprehensive income, net of tax — — — — — — 5 5 Net loss — — — — — (17,398) — (17,398) Balance as of June 30, 2025 44,137 $ 44 $ 767,261 13,650 $ (199,998) $ (12,124) $ (260) $ 554,923 The accompanying notes are an integral part of these condensed consolidated financial statements. 5 Table of Contents EHEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands, unaudited) Six Months Ended June 30, 2026 2025 Operating activities: Net loss $ (28,309) $ (15,448) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation and amortization 980 937 Amortization of internally developed software 5,569 6,468 Stock-based compensation expense 4,588 7,665 Deferred income taxes (8,657) (5,195) Impairment charges 303 413 Other non-cash items 913 (637) Changes in operating assets and liabilities: Accounts receivable 5,870 14,952 Contract assets – commissions receivable 115,508 83,486 Prepaid expenses and other assets 1,079 (514) Accounts payable (25,370) (17,627) Accrued compensation and benefits (26,131) (26,834) Accrued marketing expenses (13,403) (12,565) Deferred revenue (2,537) 328 Accrued expenses and other liabilities 407 488 Net cash provided by operating activities 30,810 35,917 Investing activities: Capitalized internal-use software and website development costs (4,345) (7,376) Purchases of property and equipment and other assets (643) (1,893) Purchases of marketable securities (48,555) (61,878) Proceeds from redemption and maturities of marketable securities 21,109 66,500 Net cash used in investing activities (32,434) (4,647) Financing activities: Net proceeds from exercise of common stock options and employee stock purchases 102 189 Repurchase of shares to satisfy employee tax withholding obligations (208) (1,826) Payments of preferred stock dividends (3,083) (2,906) Net cash used in financing activities (3,189) (4,543) Effect of exchange rate changes on cash, cash equivalents and restricted cash 309 (4) Net increase (decrease) in cash, cash equivalents and restricted cash (4,504) 26,723 Cash, cash equivalents and restricted cash at beginning of period 76,815 42,287 Cash, cash equivalents and restricted cash at end of period $ 72,311 $ 69,010 The accompanying notes are an integral part of these condensed consolidated financial statements. 6 Table of Contents EHEALTH, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Note 1 – Summary of Business and Significant Accounting Policies Description of Business – eHealth, Inc., a Delaware corporation, together with its consolidated subsidiaries (collectively, “eHealth”), is a leading private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. Our mission is to expertly guide consumers, or beneficiaries, through their health insurance enrollment and related options, when, where and how they prefer. Our platform leverages technology to solve a critical problem in a large and growing market by aiding consumers in what has traditionally been a complex, confusing and opaque health insurance purchasing process. Our omnichannel consumer engagement platform differentiates our offering from competitors and enables consumers to use our services through our self-service online platform, by telephone with a licensed and trained insurance agent, or benefit advisor, or through a hybrid online assisted interaction that includes live agent chat and co-browsing capabilities. We have created a consumer-centric marketplace that offers consumers a broad choice of insurance products that includes thousands of Medicare Advantage, Medicare Supplement, Medicare Part D prescription drug, individual, family, small business and other ancillary health insurance products from over 180 health insurance carriers nationwide, including approximately 50 Medicare health insurance carriers. Our plan recommendation tool curates this broad plan selection by analyzing consumer health-related information against plan data for insurance coverage fit. This tool is supported by a unified data platform and is available to our ecommerce consumers and our benefit advisors. We strive to be the most trusted, unbiased, transparent partner to consumers in their journeys through the health insurance market. Unless otherwise specified or required by the context, references in this Quarterly Report on Form 10-Q to “eHealth,” “the Company,” “we,” “us” or “our” mean eHealth, Inc. and its consolidated direct and indirect wholly owned subsidiaries. Basis of Presentation – The accompanying Condensed Consolidated Balance Sheet as of June 30, 2026 and other condensed consolidated financial statements for the three and six months ended June 30, 2026 and 2025 are unaudited. The Condensed Consolidated Balance Sheet as of December 31, 2025 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the Securities and Exchange Commission on February 26, 2026. The accompanying financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. The condensed consolidated financial statements include the accounts of eHealth, Inc. and its direct and indirect wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with those rules and regulations. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2025 and include all adjustments necessary for the fair presentation of our financial position as of June 30, 2026 and December 31, 2025 and our results of operations for the periods presented. The results for the three and six months ended June 30, 2026 are not necessarily indicative of the results to be expected for any subsequent period or for the year ended December 31, 2026 and therefore, should not be relied upon as an indicator of future results. Significant Accounting Policies, Estimates and Judgments — The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported and disclosed in the condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates, including those related to, but not limited to, the fair value of investments, the commissions we expect to collect for 7 Table of Contents EHEALTH, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) each approved member cohort, valuation allowance for deferred income taxes, uncertain tax positions and the assumptions used in determining stock-based compensation. We base our estimates of the carrying value of certain assets and liabilities on historical experience and on various other assumptions that we believe to be reasonable. Actual results may differ from these estimates. There have been no material changes to our significant accounting policies discussed in our Annual Report on Form 10-K for the year ended December 31, 2025. Recently Adopted Accounting Pronouncements We did not adopt any new accounting pronouncements during the six months ended June 30, 2026. Recently Issued Accounting Pronouncements Not Yet Adopted Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40) — In November 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU will require more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, intangible asset amortization and depletion) included in certain expense captions presented on the face of the income statement. The ASU is effective for fiscal years beginning after December 15, 2026 and for interim periods beginning after December 15, 2027. The ASU may be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to all prior periods presented in the financial statements and early adoption is permitted. We are currently evaluating the impact of adopting this ASU on our consolidated financial statements and related disclosures. Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40) — In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other – Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which amends the guidance in Accounting Standards Codification (“ASC”) 350-40, Intangibles-Goodwill and Other-Internal-Use-Software. This ASU amends the existing standard that refers to various stages of a software development project to align better with current software development methods, such as agile programming. The new guidance is effective for all entities for annual periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is permitted as of the beginning of an annual reporting period. The ASU can be applied on a fully prospective basis, a modified basis for in-process projects, or a full retrospective basis. We are currently evaluating the impact of adopting this ASU on our consolidated financial statements and related disclosures. Equity (Topic 505) — In April 2026, the FASB issued ASU 2026-01, Equity (Topic 505): Initial Measurement of Paid-in-Kind Dividends on Equity-Classified Preferred Stock. This ASU requires that paid-in-kind (“PIK”) dividends on equity-classified preferred stock be initially measured based on the preferred stock’s contractual PIK dividend rate. The ASU is effective for fiscal years beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. Early adoption is permitted in an interim or annual reporting period in which financial statements have not yet been issued or made available for issuance. The ASU can be applied on a fully prospective basis, or a modified retrospective basis for equity-classified preferred stock instruments that are outstanding as of the initial application date. No material impact is expected to our consolidated financial statements as our current accounting for PIK dividends is consistent with the guidance in ASU 2026-01. 8 Table of Contents EHEALTH, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Note 2 – Revenue Disaggregation of Revenue – The table below depicts the disaggregation of revenue by product and is consistent with how we evaluate our financial performance (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Medicare Medicare Advantage $ 27,862 $ 38,264 $ 87,352 $ 113,250 Medicare Supplement 2,381 13,286 8,530 21,890 Medicare Part D (1) (3,930) (1,048) 404 1,395 Total Medicare 26,313 50,502 96,286 136,535 Individual and Family (2) Non-Qualified Health Plans (1) (899) (434) (78) 484 Qualified Health Plans (1) (598) (402) (126) 1,363 Total Individual and Family (1,497) (836) (204) 1,847 Ancillary Hospital Indemnity 1,185 1,555 3,919 3,686 Dental 426 22 1,509 2,256 Vision 274 252 875 1,021 Short-term 221 362 408 732 Other 271 58 530 386 Total Ancillary 2,377 2,249 7,241 8,081 Small Business 2,242 2,297 5,736 5,731 Commission Bonus and Other 369 519 552 1,483 Total Commission Revenue 29,804 54,731 109,611 153,677 Other Revenue Sponsorship and Advertising Revenue 282 2,753 1,963 10,892 Fee-based and Other Revenue 3,480 3,298 10,010 9,332 Total Other Revenue 3,762 6,051 11,973 20,224 Total Revenue $ 33,566 $ 60,782 $ 121,584 $ 173,901 _____________ (1) Revenue was negative due to net commission revenue from members approved in prior periods. Such amounts were $(4.0) million, $(1.2) million, and $(0.7) million for Medicare Part D, non-qualified and qualified health plans, respectively, for the three months ended June 30, 2026; $(1.2) million and $(0.7) million for non-qualified and qualified health plans, respectively, for the six months ended June 30, 2026; and $(1.3) million, $(0.8) million, and $(0.7) million for Medicare Part D, non-qualified and qualified health plans, respectively, for the three months ended June 30, 2025. (2) We define our individual and family plan offerings as major medical individual and family health insurance plans, which do not include Medicare-related, small business or ancillary plans. Individual and family health insurance plans include both qualified and non-qualified plans. Qualified health plans meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-qualified health plans do not meet the requirements of the Affordable Care Act and are not offered through the government-run health insurance exchange in the relevant jurisdiction. Individuals that purchase non-qualified health plans cannot receive a subsidy in connection with the purchase of non-qualified plans. 9 Table of Contents EHEALTH, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Commission revenue by segment is presented in the table below (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Medicare Commission revenue from members approved during the period $ 19,141 $ 33,148 $ 85,579 $ 114,902 Net commission revenue from members approved in prior periods (1) 9,087 19,089 15,877 27,054 Total Medicare segment commission revenue $ 28,228 $ 52,237 $ 101,456 $ 141,956 Employer and Individual Commission revenue from members approved during the period $ 1,343 $ 1,920 $ 3,910 $ 5,778 Commission revenue from renewals of small business members during the period 1,713 1,892 4,484 4,742 Net commission revenue from members approved in prior periods (1) (1,480) (1,318) (239) 1,201 Total Employer and Individual segment commission revenue $ 1,576 $ 2,494 $ 8,155 $ 11,721 Total commission revenue from members approved during the period $ 20,484 $ 35,068 $ 89,489 $ 120,680 Commission revenue from renewals of small business members during the period 1,713 1,892 4,484 4,742 Total net commission revenue from members approved in prior periods (1)(2) 7,607 17,771 15,638 28,255 Total commission revenue $ 29,804 $ 54,731 $ 109,611 $ 153,677 _____________ (1)For all existing cohorts approved in prior periods, we reassess assumptions for our constrained lifetime value (“LTV”) of commissions on a quarterly basis and compare to the most current constrained LTV recognized on these cohorts. To the extent there is an indication of a change to expected cash collections for these cohorts, net commission revenue from members approved in prior periods, also referred to as net adjustment revenue, is recorded to adjust revenue previously recognized for the affected cohorts. Net adjustment revenue includes both increases and reductions to revenue; however, adjustments increasing revenue are only recognized when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. (2)The after-tax impact of total net commission revenue from members approved in prior periods for the three months ended June 30, 2026 and 2025 was $0.18 and $0.44 per basic and diluted share, respectively. The after-tax impact of total net commission revenue from members approved in prior periods for the six months ended June 30, 2026 and 2025 was $0.38 and $0.71 per basic and diluted share, respectively. Note 3 – Supplemental Financial Statement Information Cash, Cash Equivalents and Restricted Cash We consider all investments with an original maturity of 90 days or less from the date of purchase to be cash equivalents. Cash and cash equivalents are stated at fair value. We also invest in marketable securities that are measured and recorded at fair value. See Note 4 – Fair Value Measurements for further discussion about our marketable securities. 10 Table of Contents EHEALTH, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Our cash, cash equivalents and restricted cash balances are summarized as follows (in thousands): June 30, 2026 December 31, 2025 Cash $ 14,503 $ 58,162 Cash equivalents 55,178 15,563 Cash and cash equivalents 69,681 73,725 Restricted cash 2,630 3,090 Total cash, cash equivalents and restricted cash $ 72,311 $ 76,815 As of June 30, 2026 and December 31, 2025, we had $2.6 million and $3.1 million of restricted cash, respectively, which was classified as a non-current asset on our Condensed Consolidated Balance Sheets. This amount collateralizes letters of credit related to certain lease commitments. Contract Assets and Accounts Receivable We do not require collateral or other security for our contract assets and accounts receivable. We believe the potential for collection issues with any of our customers was minimal as of June 30, 2026. We estimate an allowance for credit losses using relevant available information from internal and external sources related to past events, current conditions and reasonable and supportable forecasts. Specifically, for the purpose of measuring the probability of default parameters, we utilize Capital IQ’s, Standard & Poor’s and Moody’s analytics. Our estimates of loss given default are determined by using our historical collections data as well as historical information obtained through our research and review of other insurance related companies. Our estimated exposure at default is determined by applying these internal and external data sources to our commissions receivable balances. As such, we apply an immediate reversion method and revert to historical loss information when computing our credit loss exposure. Credit loss expenses are assessed quarterly and included in the “General and administrative” line in our Condensed Consolidated Statements of Comprehensive Loss. There were no write-offs during the six months ended June 30, 2026 or for the year ended December 31, 2025. The change in the allowance for credit losses is summarized as follows (in thousands): June 30, 2026 December 31, 2025 Beginning balance $ 2,438 $ 2,222 Change in allowance (388) 216 Ending balance $ 2,050 $ 2,438 11 Table of Contents EHEALTH, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Our contract assets – commissions receivable activities, net of credit loss allowances, are summarized as follows (in thousands): Medicare Segment E&I Segment Total Beginning balance at December 31, 2025 $ 1,068,918 $ 53,812 $ 1,122,730 Commission revenue from members approved during the period 85,579 3,910 89,489 Commission revenue from renewals of small business members during the period — 4,484 4,484 Net commission revenue from members approved in prior periods 15,877 (239) 15,638 Cash receipts (212,125) (12,994) (225,119) Net change in credit loss allowance 369 19 388 Ending balance at June 30, 2026 $ 958,618 $ 48,992 $ 1,007,610 Credit Risk Our financial instruments that are exposed to concentrations of credit risk principally consist of cash, cash equivalents, marketable securities, contract assets – commissions receivable and accounts receivable. We invest our cash and cash equivalents with major banks and financial institutions, and, at times, such investments are in excess of federally insured limits. We also have deposits with major banks in China that are denominated in both U.S. dollars and Chinese Yuan Renminbi and are not insured by the U.S. federal government. The deposits in China were $2.5 million as of June 30, 2026. See Note 4 – Fair Value Measurements for additional information regarding our marketable securities. We do not require collateral or other security for either our contract assets or accounts receivable. Carriers, including subsidiaries, that represented 10% or more of our total contract assets – commissions receivable and accounts receivable balances are summarized as follows: June 30, 2026 December 31, 2025 Humana 34 % 33 % UnitedHealthcare 29 % 28 % Aetna 13 % 13 % Prepaid Expenses and Other Current Assets – Our prepaid expenses and other current assets are summarized as follows (in thousands): June 30, 2026 December 31, 2025 Prepaid software and maintenance contracts $ 4,889 $ 5,449 Prepaid licenses 1,370 2,335 Prepaid insurance 319 1,254 Prepaid marketing 231 1,104 Prepaid other expenses 1,719 1,787 Other current assets 1,555 1,399 Prepaid expenses and other current assets $ 10,083 $ 13,328 12 Table of Contents EHEALTH, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Note 4 – Fair Value Measurements We define fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques we use to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We classify the inputs used to measure fair value into the following hierarchy: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability. Level 3 Unobservable inputs for the asset or liability. Our financial assets measured at fair value on a recurring basis are summarized below by their classification within the fair value hierarchy as follows (in thousands): June 30, 2026 Carrying Value Level 1 Level 2 Level 3 Total Assets Cash equivalents Money market funds $ 9,086 $ 9,086 $ — $ — $ 9,086 Commercial paper 46,092 — 46,092 — 46,092 Short-term marketable securities Government securities 18,230 — 18,230 — 18,230 Commercial paper 12,140 — 12,140 — 12,140 Corporate bonds 997 — 997 — 997 Total assets measured at fair value $ 86,545 $ 9,086 $ 77,459 $ — $ 86,545 December 31, 2025 Carrying Value Level 1 Level 2 Level 3 Total Assets Cash equivalents Money market funds $ 15,563 $ 15,563 $ — $ — $ 15,563 Short-term marketable securities Commercial paper 3,495 — 3,495 — 3,495 Total assets measured at fair value $ 19,058 $ 15,563 $ 3,495 $ — $ 19,058 We endeavor to utilize the best available information in measuring fair value. Our money market funds are measured at fair value based on quoted prices in active markets and are classified as Level 1 within the fair value hierarchy. Our available for sale marketable securities, which include government securities, commercial paper and corporate bonds, are measured at fair value using quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs and are classified as Level 2 within the fair value hierarchy. There were no transfers between the hierarchy levels during the six months ended June 30, 2026 or the year ended December 31, 2025. 13 Table of Contents EHEALTH, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) The following table summarizes our cash equivalents and available for sale debt securities by contractual maturity (in thousands): As of June 30, 2026 As of December 31, 2025 Amortized Cost Fair Value Amortized Cost Fair Value Due in 1 year $ 84,805 $ 84,775 $ 19,058 $ 19,058 Due in 1 year through 5 years 1,770 1,770 — — Total $ 86,575 $ 86,545 $ 19,058 $ 19,058 All marketable securities, including those that have contractual maturities greater than one year, have been classified as short-term based on their readily liquid nature and because they represent the investment of cash that is available to support current operations. Unrealized gains and losses on available for sale debt securities that are not credit related are included in accumulated other comprehensive income (loss) and summarized as follows (in thousands): June 30, 2026 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Cash equivalents Money market funds $ 9,086 $ — $ — $ 9,086 Commercial paper 46,100 — (8) 46,092 Short-term marketable securities Government securities 18,249 — (19) 18,230 Commercial paper 12,143 — (3) 12,140 Corporate bonds 997 — — 997 Total $ 86,575 $ — $ (30) $ 86,545 December 31, 2025 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Cash equivalents Money market funds $ 15,563 $ — $ — $ 15,563 Short-term marketable securities Commercial paper 3,495 — — 3,495 Total $ 19,058 $ — $ — $ 19,058 As of June 30, 2026, we had 46 securities in a net unrealized loss position that were immaterial individually and in aggregate. As of December 31, 2025, we had no securities in a net unrealized loss position. We did not record any credit losses regarding our available for sale debt securities during the six months ended June 30, 2026 and 2025. We do not intend to sell these securities at a significant loss as we have the ability to hold them until maturity, and it is more likely than not that we will not be required to sell these securities before the recovery of their amortized cost basis. We recognized interest income of $0.9 million and $1.2 million for the three months ended June 30, 2026 and 2025, and $1.8 million and $2.6 million for the six months ended June 30, 2026 and 2025, respectively. 14 Table of Contents EHEALTH, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Note 5 – Equity 2024 Equity Incentive Plan – On June 18, 2026, upon approval at our annual meeting of stockholders, we amended and restated our Amended and Restated 2024 Equity Incentive Plan (as amended and restated, the “A&R 2024 Equity Plan”) to reserve an additional 1,300,000 shares of our common stock that may be issued thereunder. Stock Repurchase Programs – We had no stock repurchase activity during the three and six months ended June 30, 2026 or 2025 and had 10.7 million shares previously repurchased under our past repurchase programs. For accounting purposes, common stock repurchased under our stock repurchase programs is recorded based upon the settlement date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method. In addition, as of June 30, 2026 and 2025, we had 3.2 million and 3.0 million shares, respectively, in treasury that were previously surrendered by employees to satisfy tax withholding due in connection with the vesting of certain restricted stock units. As of June 30, 2026 and 2025, we had a total of 13.9 million and 13.7 million shares, respectively, held in treasury. Beginning in the first quarter of 2026, we changed our methodology for processing of employee tax remittances upon the vesting of stock-based equity awards from withholding shares to selling a portion of vested shares to cover the applicable withholding tax obligations (sell-to-cover). No shares are transferred to the Company’s treasury stock in connection with tax withholdings funded by sell-to-cover transactions. We continue to settle by withholding shares in connection with stock-based equity award settlements for certain employee insiders who are subject to short-swing profit rules. Stock-Based Compensation Expense – Our stock-based compensation expense is summarized by award types for the periods presented below (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Restricted stock units $ 2,122 $ 3,172 $ 4,169 $ 6,309 Performance-based stock units 173 500 341 946 Employee stock purchase program 35 53 78 93 Common stock options — 151 — 317 Total stock-based compensation expense $ 2,330 $ 3,876 $ 4,588 $ 7,665 Related tax benefit recognized $ 567 $ 935 $ 1,116 $ 1,846 The following table summarizes stock-based compensation expense by operating function for the periods presented (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Marketing and advertising $ 380 $ 585 $ 648 $ 1,082 Customer care and enrollment 224 332 448 596 Technology and content 371 680 699 1,368 General and administrative 1,355 2,279 2,793 4,619 Total stock-based compensation expense $ 2,330 $ 3,876 $ 4,588 $ 7,665 Amount capitalized for internal-use software 26 140 51 248 Total stock-based compensation $ 2,356 $ 4,016 $ 4,639 $ 7,913 15 Table of Contents EHEALTH, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Note 6 — Convertible Preferred Stock Pursuant to an investment agreement dated February 17, 2021 with Echelon Health SPV, LP (“H.I.G.”), an investment vehicle of H.I.G. Capital (the “H.I.G. Investment Agreement”), we issued and sold to H.I.G., in a private placement, 2,250,000 shares of Series A convertible preferred stock (the “Series A Preferred Stock”), par value $0.001 per share, at an aggregate purchase price of $225.0 million on April 30, 2021 (the “Closing Date”). We received $214.0 million in net proceeds from the private placement with H.I.G., net of sales commissions and certain transaction fees totaling $11.0 million. On December 31, 2025, in connection with our entry into the revolving credit facility with CCP Agency, LLC (the “Revolving Credit Facility”), we entered into a first amendment to the H.I.G. Investment Agreement (the “H.I.G. Investment Agreement Amendment”), which amends the H.I.G. Investment Agreement to, among other things, (i) explicitly permit entry into, borrowings under, and refinancing of the Revolving Credit Facility up to the initial $125.0 million in Aggregate Revolving Loan Commitments, as defined in the H.I.G. Investment Agreement Amendment, plus in the case of refinancings, certain additional amounts, (ii) add a liquidity covenant substantially similar to the covenant provided for in the Revolving Credit Facility, with the sole remedy for breach of the liquidity covenant being a 2.00% increase in the paid-in-kind dividend rate as described below, (iii) establish H.I.G.’s rights with respect to a new strategy committee of the Company’s board of directors, including the right to designate one member and an observer to the committee, and (iv) provide certain additional governance and covenant protections to H.I.G., including with respect to additional debt incurrence and information rights related to the Company’s annual budget. For further information on the Revolving Credit Facility, see Note 12 - Debt. Our Series A Preferred Stock is considered temporary equity in our Condensed Consolidated Balance Sheets and we have determined there are no material embedded features that require recognition as a derivative asset or liability. The Series A Preferred Stock ranks senior to all other equity securities of the Company with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. The H.I.G. Investment Agreement Amendment had no impact on the classification or measurement of our Series A Preferred Stock as no substantive terms were modified. Voting Rights – The Series A Preferred Stock votes together with the common stock as a single class on all matters submitted to a vote of the holders of the common stock in accordance with the Certificate of Designations of Series A Preferred Stock, as filed with the Secretary of State of the State of Delaware on April 30, 2021 and as amended on December 31, 2025 (collectively, the “Certificate of Designations”). Dividends – The Series A Preferred Stock participates, on an as-converted basis, in all dividends paid to the holders of our common stock. From April 30, 2021 through June 30, 2023, dividends accrued at 8% per annum on the stated value of $100 per share, payable in kind (“PIK”). Subsequent to June 30, 2023, dividends accrue at 8% per annum, with 6% PIK and 2% payable in cash in arrears. Dividends compound semiannually and are PIK and payable in cash in arrears, as applicable, on June 30 and December 31 of each year. PIK dividends are cumulative and are added to the Accrued Value, as defined in the H.I.G. Investment Agreement. During the second quarter of 2026, we made a cash dividend payment of $3.1 million. Board Nomination Rights – As of June 30, 2026, H.I.G. has designated one member and one board observer to the Company’s Board of Directors. Conversion Rights – The Series A Preferred Stock is convertible at any time into common stock at a conversion rate (the “Conversion Price”) and is subject to further adjustment and the number of shares of common stock issuable upon conversion is subject to certain limitations, each as set forth in the H.I.G. Investment Agreement. As of June 30, 2026, the Conversion Price was equal to $79.5861 per share. Mandatory Conversion of the Series A Preferred Stock by the Company – At any time on or after the third anniversary of the Closing Date, if the volume-weighted average price per share of our common stock is greater than 167.5% of the then-current Conversion Price for 20 consecutive trading days in a 30-day trading day period, the Company will have the right to convert all, but not less than all, of the Series A Preferred Stock into common stock at a conversion rate in accordance with the Certificate of Designations. 16 Table of Contents EHEALTH, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Redemption Put Right – At any time on or after the sixth anniversary of the Closing Date, holders of the Series A Preferred Stock have the right to cause the Company to redeem out of legally available funds all or any portion of the Series A Preferred Stock in cash at an amount equal to the greater of (i) 135% of the Accrued Value per share as of the redemption date, plus accrued PIK dividends that have not yet been added to the Accrued Value and (ii) the amount per share that would be payable on an as-converted basis on such Series A Preferred Stock at the then-current Accrued Value, plus accrued PIK dividends that have not yet been added to the Accrued Value, and in either case of (i) or (ii) plus any unpaid cash dividends that would have otherwise been settled in cash in connection with such conversion (the greater of (i) and (ii), the “Redemption Price”). Redemption Call Right – At any time on or after the sixth anniversary of the Closing Date, the Company has the right (but not the obligation) to redeem out of legally available funds and for cash consideration all (but not less than all) of the Series A Preferred Stock upon at least 30 days prior written notice at an amount equal to the Redemption Price. Covenants and Liquidity Requirements – As long as H.I.G. continues to own at least 30% of the Series A Preferred Stock originally issued to it in the private placement, the consent of H.I.G. is required for the Company to incur certain indebtedness and to take certain other corporate actions as set forth in the H.I.G. Investment Agreement. The Company is required to maintain an Asset Coverage Ratio (as defined in the H.I.G. Investment Agreement), which was 2.5x from August 2023 onwards. Additionally, the H.I.G. Investment Agreement requires the Company to maintain a Minimum Liquidity Amount (as defined in the H.I.G. Investment Agreement) for certain periods that ranges from $65.0 million to $125.0 million. Failure to maintain the Minimum Asset Coverage Ratio or the Minimum Liquidity Amount as of the date or for the time period required by the H.I.G. Investment Agreement, for as long as H.I.G. continues to own at least 30% of the Series A Preferred Stock originally issued to it in the private placement, entitles H.I.G., subject to conditions and restrictions specified therein, to additional rights, including the right to nominate one additional member to the Company’s Board of Directors, the right to approve the Company’s annual budget, the right to approve hiring or termination of certain key executives, and the right to approve the incurrence of certain indebtedness. As of September 30, 2023, we failed to maintain the Minimum Asset Coverage Ratio, which entitles H.I.G. to the additional rights set forth above. On March 13, 2024, the Nominating and Corporate Governance Committee of our Board of Directors approved the appointment of a board observer designated by H.I.G. As of November 30, 2024, we were no longer in compliance with the Minimum Liquidity Amount. The non-compliance with the Minimum Asset Coverage Ratio or the Minimum Liquidity Amount does not entitle H.I.G. to accelerate the redemption of the Series A Preferred Stock. The H.I.G. Investment Agreement Amendment adds an additional liquidity covenant in which our Unrestricted Cash, as defined in the H.I.G. Investment Agreement Amendment, shall be no less than $45.0 million as of the last day of each calendar month for as long as H.I.G. continues to own at least 30% of the Series A Preferred Stock originally issued to it in the private placement. Failure to maintain the minimum Unrestricted Cash balance will result in a PIK dividend accrual rate of 8.00% per annum until the later of (a) the date on which we cure such breach, violation or failure and (b) the one-year anniversary of the date on which such breach, violation or failure first occurred. As of June 30, 2026, we were in compliance with the additional liquidity covenant. As of June 30, 2026, the estimated Series A Preferred Stock redemption value equals 135% of the Accrued Value per share as of the redemption date, plus accrued PIK dividends that have not yet been added to the Accrued Value, which is significantly in excess of the fair value of the common stock into which the Series A Preferred Stock is convertible as of June 30, 2026. We have elected to apply the accretion method to adjust the carrying value of the Series A Preferred Stock to its redemption value at the earliest date of redemption, April 30, 2027. Amounts recognized to accrete the Series A Preferred Stock to its estimated redemption value are treated as a deemed dividend and are recorded as a reduction to retained earnings, to the extent available, and if not, are recorded as a reduction to additional-paid-in-capital. The estimated redemption value will vary in subsequent periods due to the redemption put right described above and we have elected to recognize such changes prospectively. No shares of Series A Preferred Stock have been converted, and the Series A Preferred Stock was convertible into 4.0 million shares of common stock as of June 30, 2026. 17 Table of Contents EHEALTH, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) The following table summarizes the proceeds and changes to our Series A Preferred Stock (in thousands): Gross proceeds $ 225,000 Less: issuance costs (10,975) Net proceeds $ 214,025 Balance as of December 31, 2025 $ 382,057 Accrued paid-in-kind dividends 9,251 Change in preferred stock redemption value 14,975 Balance as of June 30, 2026 $ 406,283 Note 7 – Net Loss Per Share Attributable to Common Stockholders Our Series A Preferred Stock is considered a participating security, which requires the use of the two-class method for the computation of basic and diluted per share amounts. Under the two-class method, earnings available to common stockholders for the period are allocated between common stockholders and participating securities according to dividends accumulated and participation rights in undistributed earnings. Net loss attributable to common stockholders is not allocated to the convertible preferred stock as the holder of the Series A Preferred Stock does not have a contractual obligation to share in losses. Basic net loss attributable to common stockholders per share is computed by dividing net loss available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss attributable to common stockholders per share is computed by dividing the net loss available to common stockholders for the period by the weighted average number of common and common equivalent shares outstanding during the period. Diluted net loss attributable to common stockholders per share reflects all potential dilutive common stock equivalent shares, including conversion of preferred stock, stock options, restricted stock units and shares to be issued under our employee stock purchase program. The following table sets forth the computation of basic and diluted net loss attributable to common stockholders per share (in thousands, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Numerator: Net loss attributable to common stockholders $ (37,511) $ (29,783) $ (55,618) $ (39,755) Denominator: Shares used in per share calculation – basic 31,780 30,404 31,458 30,202 Dilutive effect of common stock — — — — Shares used in per share calculation – diluted 31,780 30,404 31,458 30,202 Net loss attributable to common stockholders per share – basic and diluted $ (1.18) $ (0.98) $ (1.77) $ (1.32) 18 Table of Contents EHEALTH, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) For each of the three and six months ended June 30, 2026 and 2025, we had securities outstanding that could potentially dilute net loss per share, but the shares from the assumed conversion or exercise of these securities were excluded in the computation of diluted net loss per share as their effect would have been anti-dilutive. The number of weighted-average outstanding anti-dilutive shares that were excluded from the computation of diluted net loss per share consisted of the following (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Convertible preferred stock 3,962 3,735 3,933 3,708 Restricted stock units 1,864 2,038 2,133 1,676 Performance-based stock units 1,135 385 1,135 420 Common stock options 100 211 100 212 Employee stock purchase program 94 45 7 15 Total 7,155 6,414 7,308 6,031 Note 8 – Commitments and Contingencies Service and Licensing Obligations We have entered into service and licensing agreements with third-party vendors to provide various services, including network access, equipment maintenance and software licensing. As the benefits of these agreements are experienced uniformly over the applicable contractual periods, we record the related service and licensing expenses on a straight-line basis, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements. Our future minimum payments under non-cancellable contractual service and licensing obligations as of June 30, 2026 were as follows (in thousands): Year ending December 31, 2026 (remainder) $ 5,757 2027 3,826 2028 652 2029 — 2030 — Thereafter — Total $ 10,235 Operating Leases Refer to Note 10 – Leases for commitments related to our operating leases. Self-Insurance We provide comprehensive major medical benefits to our employees. We maintain a substantial portion of our U.S. employee health insurance benefits on a self-insured basis with up to $0.3 million per individual per year with the maximum claim liability as of June 30, 2026 of $30.3 million. As a result, we record a self-insurance liability based on claims filed and an estimate of claims incurred but not yet reported. As of June 30, 2026 and 19 Table of Contents EHEALTH, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) December 31, 2025, we had a self-insurance liability balance of $3.1 million and $2.6 million, respectively, in the “Accrued compensation and benefits” line on our Condensed Consolidated Balance Sheets. Contingencies From time to time, we receive inquiries from governmental bodies and also may be subject to various legal proceedings and claims arising in the ordinary course of business. We assess contingencies to determine the degree of probability and range of possible loss for potential accrual in our condensed consolidated financial statements. An estimated loss contingency is accrued in the condensed consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. As of June 30, 2026, we have not recorded any material litigation-related accruals for loss contingencies associated with legal proceedings or matters or have determined that an unfavorable outcome is reasonably possible or estimable. Legal proceedings or other contingencies may be material to our results of operations, financial condition or cash flows, even if we ultimately prevail, and we may from time to time enter into settlements to resolve such litigation. Legal costs incurred in connection with the resolution of claims, lawsuits and other contingencies generally are expensed as incurred. Legal Proceedings On May 1, 2025, we became aware that the United States District Court for the District of Massachusetts (the “Court”) unsealed a qui tam action, United States ex rel. Andrew Shea v. eHealth, Inc. et al, against numerous insurance carriers and insurance brokers, including eHealth, Inc. and its subsidiary, eHealthInsurance Services, Inc. The Relator’s lawsuit, originally filed under seal on November 2, 2021, was brought by a former eHealth marketing representative pursuant to the qui tam provision of the Federal False Claims Act. The Relator’s complaint alleges that eHealth, Inc. and eHealthInsurance Services, Inc., along with other insurance carriers and insurance brokers, violated the Federal False Claims Act through certain Medicare Advantage enrollment and marketing activities. The Relator’s complaint seeks, among other things, treble damages, civil penalties and costs. The Court’s May 1, 2025 order also unsealed the government’s notice of election to intervene in part in the qui tam action, as well as the government’s Complaint in Partial Intervention. The government’s Complaint brings similar claims under the Federal False Claims Act against certain defendants named in the Relator’s complaint, including eHealth, Inc. and eHealthInsurance Services, Inc. On August 19, 2025, eHealth jointly filed two motions to dismiss all claims against eHealth, and on December 9, 2025, eHealth filed a motion for leave to depose the Relator regarding certain eHealth privileged documents found to be in the Relator’s possession. The parties fully briefed both motions, which were heard by the Court on January 21, 2026. On March 25, 2026, the Court issued its opinion denying both motions except with respect to the government’s claim for unjust enrichment, which was dismissed. On May 22, 2026, eHealth filed its answer to the government’s complaint, and on May 27, 2026, the Court issued a scheduling order setting discovery and dispositive motion deadlines and limits. Note 9 – Segment and Geographic Information Reportable Segments Our operating and reportable segments have been determined in accordance with ASC 280, Segment Reporting. Our business structure is comprised of two reportable operating segments: (i) Medicare and (ii) Employer and Individual (“E&I”). Our Medicare segment includes operating segments that have been aggregated based on the nature of products and services, types or class of customers, methods used to distribute the products and services, the nature of the regulatory environment and similarity of economic characteristics. The Medicare segment consists primarily of commissions earned as the broker of record from our sale of Medicare-related health insurance plans, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans, and to a lesser extent, ancillary products sold to our Medicare-eligible beneficiaries, including but not limited to, dental and vision insurance and hospital indemnity plans. Our commissions may include 20 Table of Contents EHEALTH, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) certain bonus payments, which are generally based on attaining predetermined target sales levels or other objectives, as determined by the health insurance carriers. The Medicare segment also consists of amounts earned in connection with our advertising programs, including other services such as marketing, as well as amounts earned from our non-broker of record fee-based arrangements and our performance of various post-enrollment services for members. The E&I segment consists primarily of commissions earned from our sale of individual and family plans, including both qualified and non-qualified plans, employer plans, including small business health insurance plans, Individual Coverage Health Reimbursement Arrangements (“ICHRAs”), and ancillary products sold to our non-Medicare-eligible consumers, including but not limited to, dental, vision and short-term insurance. To a lesser extent, the E&I segment also includes amounts earned from our online sponsorship program that allows carriers to purchase advertising space in specific markets on our website as well as our technology licensing activities. We report segment information based on how our chief executive officer, who is our chief operating decision maker (“CODM”), regularly reviews our operating results, allocates resources and makes decisions regarding our business operations in the annual budget and forecasting process along with evaluation of actual performance. Our CODM considers budget-to-actual variances on a monthly basis for our segment performance measures when making decisions about allocating capital and personnel to our segments. These performance measures include total segment revenue and segment gross profit (loss). Segment gross profit (loss) is calculated as total revenue for the applicable segment less variable marketing and advertising expenses, segment customer care and enrollment (“CC&E”) expenses and cost of revenue for the applicable segment. Variable marketing and advertising expenses represent costs incurred in member acquisition from our direct marketing and marketing partner channels and exclude fixed overhead costs, such as personnel related costs, consulting expenses and other operating costs allocated to the marketing and advertising department. Segment CC&E expenses include expenses we incur in assisting applicants during the enrollment process and exclude operating costs allocated to the CC&E department. The results of our reportable segments are summarized for the periods presented below (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Medicare: Total revenue $ 31,799 $ 58,059 $ 113,070 $ 161,728 Variable marketing and advertising (5,793) (13,800) (24,522) (47,553) Medicare CC&E (19,832) (25,078) (49,444) (59,547) Cost of revenue (210) (36) (104) 264 Medicare segment gross profit $ 5,964 $ 19,145 $ 39,000 $ 54,892 21 Table of Contents EHEALTH, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Employer and Individual: Total revenue $ 1,767 $ 2,723 $ 8,514 $ 12,173 Variable marketing and advertising (613) (717) (1,456) (1,907) E&I CC&E (1,939) (2,201) (4,081) (4,381) Cost of revenue (55) (62) (121) (154) E&I segment gross profit (loss) $ (840) $ (257) $ 2,856 $ 5,731 Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Consolidated: Total revenue $ 33,566 $ 60,782 $ 121,584 $ 173,901 Variable marketing and advertising (6,406) (14,517) (25,978) (49,460) Segment CC&E (21,771) (27,279) (53,525) (63,928) Cost of revenue (265) (98) (225) 110 Total segment gross profit $ 5,124 $ 18,888 $ 41,856 $ 60,623 A reconciliation of our total segment gross profit to the Condensed Consolidated Statements of Comprehensive Loss for the periods presented is as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Total segment gross profit $ 5,124 $ 18,888 $ 41,856 $ 60,623 Other marketing and advertising (1) (5,110) (6,810) (10,971) (13,264) Other CC&E (2) (527) (631) (1,057) (1,203) Technology and content (11,301) (11,354) (22,636) (23,955) General and administrative (15,583) (21,582) (31,095) (38,892) Impairment, restructuring and other charges (60) (1,555) (6,432) (1,555) Interest expense (4,054) (2,348) (8,089) (4,996) Other income, net 832 1,340 1,672 2,916 Loss before income taxes $ (30,679) $ (24,052) $ (36,752) $ (20,326) __________ (1)Other marketing and advertising costs consist of fixed marketing and advertising, previously capitalized labor, depreciation and share-based compensation costs. (2)Other CC&E costs consist of previously capitalized labor, depreciation and share-based compensation costs. There were no inter-segment revenue transactions for the periods presented. With the exception of contract assets – commissions receivable, which is presented by segment in Note 3 – Supplemental Financial Statement Information, our CODM does not separately evaluate assets by segment, and therefore, assets by segment are not presented. 22 Table of Contents EHEALTH, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Geographic Information Our long-lived assets primarily consist of property and equipment, net, and internally developed software. Our long-lived assets are attributed to the geographic location in which they are located. Long-lived assets by geographical area are summarized as follows (in thousands): June 30, 2026 December 31, 2025 United States $ 25,659 $ 27,686 China 346 374 Total $ 26,005 $ 28,060 Significant Customers Substantially all revenue for the three and six months ended June 30, 2026 and 2025 was generated from customers located in the United States. Carriers representing 10% or more of our total revenue are summarized as follows. The percentages include revenue attributable to each carrier and its subsidiaries. The majority of the revenue was from the Medicare segment. Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Humana 26 % 23 % 34 % 23 % UnitedHealthcare 25 % 27 % 22 % 25 % Health Care Service Corporation 13 % 9 % 10 % 3 % Aetna 3 % 12 % 2 % 13 % Note 10 – Leases Our lease portfolio primarily consists of operating leases for office space, and our leases have remaining lease terms of less than 1 year to 4 years. Certain of these leases have free or escalating rent payment provisions. We recognize lease expense on a straight-line basis over the terms of the leases, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements. Most leases include options to renew, and the exercise of these options is at our discretion. Subsequent to becoming a remote first workplace in the third quarter of 2022, we executed several subleases of our office space in the United States. The subleases run through the remaining term of the primary leases. As of June 30, 2026, we expect to generate a total of $8.8 million in future sublease income through January 31, 2030. Sublease income is recorded on a straight-line basis as a reduction of lease expense in our Condensed Consolidated Statements of Comprehensive Loss. We test right-of-use assets when impairment indicators are present in accordance with the asset impairment provisions of ASC 360, Property, Plant and Equipment. As a result of becoming a remote first workplace, we have assessed our occupied leased office space to identify excess space to vacate and potentially sublease. We have also periodically reassessed current market conditions in our previously vacated leased office spaces that have not yet been subleased. In instances where we determined impairment indicators were present at that time of our reassessment, we tested our right-of-use assets, including leasehold improvements, for impairment. We utilized an income approach to value the asset groups by performing a discounted cash flow analysis and determined that for certain leases the net carrying values exceeded the estimated discounted future cash flows expected to be derived from the properties based on Level 3 inputs, including current sublease market rent, future sublease market conditions and the discount rate. We recorded $0.1 million of impairment charges related to our 23 Table of Contents EHEALTH, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) operating lease right-of-use assets for the three and six months ended June 30, 2026 in the “Impairment, restructuring and other charges” line in our Condensed Consolidated Statements of Comprehensive Loss. We recorded $0.4 million impairment charges related to our operating lease right-of-use assets for the three and six months ended June 30, 2025 in the “Impairment, restructuring and other charges” line in our Condensed Consolidated Statements of Comprehensive Loss. The components of operating lease costs for the three and six months ended June 30, 2026 and 2025 were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Operating lease expense $ 903 $ 1,198 $ 1,924 $ 2,416 Operating sublease income (736) (689) (1,473) (1,378) Total operating lease cost $ 167 $ 509 $ 451 $ 1,038 Supplemental information related to our leases is as follows (dollars in thousands): Six Months Ended June 30, 2026 2025 Cash paid for amounts included in the measurement of operating lease liabilities $ 4,399 $ 4,570 June 30, 2026 December 31, 2025 Weighted-average remaining lease term (in years) of operating leases 2.8 3.1 Weighted-average discount rate used to recognize operating lease right-of-use-assets 5.8 % 5.7 % As of June 30, 2026, maturities of our operating lease liabilities are as follows (in thousands): Year ending December 31, 2026 (remainder) $ 3,977 2027 6,950 2028 4,998 2029 3,008 2030 196 Thereafter — Total lease payments (1) $ 19,129 Less imputed interest (1,564) Total $ 17,565 ____________ (1)Non-cancellable sublease proceeds for the remainder of 2026 and the years ending December 31, 2027, 2028, 2029 and 2030 of $1.6 million, $3.2 million, $3.3 million, $1.4 million and $0.1 million, respectively, are not included in the table above. There will be no sublease proceeds in the years after December 31, 2030. 24 Table of Contents EHEALTH, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Note 11 — Impairment, Restructuring and Other Charges The following table details impairment, restructuring and other charges for each of the periods presented (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Asset impairment charges $ 303 $ 413 $ 303 $ 413 Restructuring and reorganization charges (243) 1,142 6,129 1,142 Impairment, restructuring and other charges $ 60 $ 1,555 $ 6,432 $ 1,555 Asset Impairments During the three and six months ended June 30, 2026, we recognized non-cash, pre-tax asset impairment charges of $0.3 million in the “Impairment, restructuring and other charges” line in our Condensed Consolidated Statements of Comprehensive Loss. These charges were comprised of $0.2 million related to abandoned internally developed software projects and $0.1 million related to operating lease right-of-use asset impairments for certain vacated leased office spaces. During the three and six months ended June 30, 2025 we recognized non-cash, pre-tax asset impairment charges of $0.4 million, related to operating lease right-of-use asset impairments for certain vacated leased office spaces in the “Impairment, restructuring and other charges” line in our Condensed Consolidated Statements of Comprehensive Loss. Refer to Note 10 – Leases for additional information related to our lease impairment charges. Restructuring Our restructuring and reorganization costs and liabilities consist primarily of severance, transition and other related costs. The following table summarizes the cash-based restructuring and reorganization related liabilities (in thousands): Balance at December 31, 2025 $ — Restructuring and reorganization charges 6,426 Payments (6,114) Adjustment to accrual (297) Balance at June 30, 2026 $ 15 During the three months ended June 30, 2026, we recognized $(0.2) million of pre-tax restructuring charges which consisted of $0.1 million of additional restructuring charges related to employee termination benefits associated with our workforce reduction initiative and a $0.3 million reduction of previously accrued restructuring costs. During the six months ended June 30, 2026, we recognized $6.1 million of pre-tax restructuring charges related to employee termination benefits resulting from our workforce reduction of approximately 14% across the organization, implemented as part of cost reduction efforts to support our strategic initiatives. These charges were recorded in the “Impairment, restructuring and other charges” line in our Condensed Consolidated Statements of Comprehensive Loss, and substantially all of the restructuring charges have been settled in cash. As of June 30, 2026, we had an immaterial restructuring accrual on our Condensed Consolidated Balance Sheet. During the three and six months ended June 30, 2025, we recorded $1.1 million of pre-tax restructuring charges in the “Impairment, restructuring and other charges” line in our Condensed Consolidated Statements of Comprehensive Loss, primarily related to employee termination benefits as a result of macroeconomic changes and internal restructuring initiatives. 25 Table of Contents EHEALTH, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Note 12 – Debt Revolving Credit Facility On December 31, 2025 (the “Closing Date”), eHealthInsurance Services, Inc. (the “Borrower”), a wholly-owned indirect subsidiary of eHealth, Inc., entered into a credit agreement (the “Revolving Credit Agreement”) with CCP Agency, LLC, as agent (the “Agent”), and the lenders party thereto. The Revolving Credit Agreement provides for an asset-based revolving credit facility (the “Revolving Credit Facility”) with aggregate commitments of $125.0 million (the “Aggregate Revolving Loan Commitment”). The Borrower has the ability to request an increase to the Aggregate Revolving Loan Commitment under the Revolving Credit Agreement by an additional amount of up to $50.0 million, provided we receive commitments for such increase and satisfy certain other conditions. The amount available for us to borrow under the Revolving Credit Facility is equal to the lesser of the Aggregate Revolving Loan Commitment and the Borrowing Base, as defined by the Revolving Credit Agreement. As of December 31, 2025, we borrowed $125.0 million of revolving loans available under the Revolving Credit Facility. A portion of the proceeds were used to repay in full all obligations outstanding under the term loan credit facility with Blue Torch Finance LLC, and to pay fees and expenses associated with the transactions contemplated by the Revolving Credit Agreement and the H.I.G. Investment Agreement Amendment. The remaining proceeds are being used for working capital and general corporate purposes. The obligations under the Revolving Credit Facility are guaranteed by Amplify Engagement Solutions Insurance Agency, LLC, the direct parent of the Borrower, and certain of the Company’s current and future subsidiaries (collectively, the “Guarantors”) and are secured by a first-priority lien on substantially all assets of the Borrower and the Guarantors, subject to certain carve-outs and exceptions. The Revolving Credit Facility matures in December 2028. Borrowings under the Revolving Credit Agreement currently bear interest at the one-month Term SOFR (as defined in the Revolving Credit Agreement, subject to a floor of 2.00% per annum), plus an applicable margin of 6.50% per annum, and, under certain specified circumstances, may be calculated at the base rate (which is the highest of (1) the prime rate on such day, (2) the then-current federal funds rate set by the Federal Reserve Bank of New York, plus 0.50% per annum, (3) the one-month Term SOFR rate published, plus 2.00% per annum, and (4) 3.00% per annum), plus an applicable margin of 5.50% per annum. As of June 30, 2026, the interest rate was 10.14%. For the three and six months ended June 30, 2026, we incurred interest expense of $3.2 million and $6.4 million, respectively. We may voluntarily prepay the revolving loans under the Revolving Credit Facility in whole or in part, up to two times in any twelve-month period (when taken together with any borrowings after the Closing Date), and reduce or cancel commitments under the Revolving Credit Facility, in each case subject to notice requirements, minimum amounts and prepayment premiums. We must prepay outstanding borrowings under the Revolving Credit Facility upon the occurrence of certain mandatory prepayment events, as set forth in the Revolving Credit Agreement. Financial covenants in the Revolving Credit Agreement require that we maintain a maximum total leverage ratio, a minimum unrestricted cash balance and a minimum lifetime value to acquisition cost ratio, each as defined in the Revolving Credit Agreement. Additionally, the Revolving Credit Agreement contains customary affirmative and negative covenants that limit the ability of the Borrower and its subsidiaries or the Guarantors, as applicable, to, among other things: (i) incur additional debt or issue certain preferred stock; (ii) pay dividends, redeem stock, or make other distributions; (iii) make other restricted payments or investments; (iv) grant liens or security interests on assets; (v) transfer or sell assets; (vi) create restrictions on payment of dividends or other amounts; (vii) engage in mergers or consolidations; or (viii) engage in certain transactions with affiliates, in each case, subject to certain carve outs and exceptions. The Revolving Credit Agreement also contains various events of default, such as a default in the performance or observance of any covenant (subject to cure periods and materiality thresholds). Upon the occurrence and during the continuance of an event of default, the Agent is entitled to take various actions, including the acceleration of all amounts due under the Revolving Credit Agreement. As of June 30, 2026, we were in compliance with our Revolving Credit Agreement covenants. 26 Table of Contents EHEALTH, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) We incurred closing costs of $12.0 million, which were recorded as a direct deduction from the face of the loan on our Condensed Consolidated Balance Sheet. Total amortization of closing costs, or debt issuance costs, was $0.8 million and $1.6 million for the three and six months ended June 30, 2026, respectively, and is recorded in the “Interest expense” line in our Condensed Consolidated Statements of Comprehensive Loss. There were $10.4 million unamortized issuance costs as of June 30, 2026. The carrying value of the Revolving Credit Agreement approximated the fair value, based on Level 2 inputs (observable market prices in less than active markets), as the interest rate is variable over the selected interest period and is similar to current rates at which we can borrow funds. The carrying value of the revolving loans was $114.6 million as of June 30, 2026. Term Loan Credit Facility On February 28, 2022, we entered into a term loan credit agreement, which provided for a $70.0 million secured term loan credit facility. The term loan credit agreement (as amended on August 16, 2022, November 1, 2024, and October 6, 2025, the “Credit Agreement”), had a maturity date of January 2027, upon which the outstanding obligations under the Credit Agreement were payable in full. The loans under the Credit Agreement bore interest, at our option, at either a rate based on the Adjusted Term SOFR or a base rate, in each case plus a margin. The base rate was the highest of the prime rate, the federal funds rate plus 0.50% and three-month Adjusted Term SOFR plus 1.00%. The margin was 7.00% for Adjusted Term SOFR loans and 6.00% for base rate loans. As of June 30, 2025, the interest rate was 11.59% and we incurred interest expense of $2.1 million and $4.1 million for the three and six months ended June 30, 2025, respectively. Total amortization of closing costs and extension fees, or debt issuance costs, was $0.3 million and $0.6 million for the three and six months ended June 30, 2025, respectively, and is recorded in the “Interest expense” line in our Condensed Consolidated Statements of Comprehensive Loss. Furthermore, as part of the Credit Agreement, we incurred a $0.3 million fee per annum, payable annually. On December 31, 2025, the Credit Agreement was terminated in connection with the execution of the Revolving Credit Agreement. The outstanding balance of $70.0 million, including an early termination fee of $0.7 million, was repaid in full and we wrote off $0.5 million of deferred issuance costs related to the Credit Agreement during the three months ended December 31, 2025. Note 13 – Income Taxes The following table summarizes our benefit from income taxes and our effective tax rates for the periods presented (in thousands, except effective tax rate): Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Loss before income taxes $ (30,679) $ (24,052) $ (36,752) $ (20,326) Benefit from income taxes (7,084) (6,654) (8,443) (4,878) Effective tax rate 23.1 % 27.7 % 23.0 % 24.0 % For the three and six months ended June 30, 2026 and 2025 we calculated our benefit from income taxes by applying an estimate of the annual effective tax rate to loss before income taxes for the reporting period. For the three and six months ended June 30, 2026, we recorded a benefit from income taxes of $7.1 million and $8.4 million, respectively, representing an effective tax rate of 23.1% and 23.0%, respectively, which was higher than the statutory federal tax rate primarily due to state taxes, stock-based compensation adjustments and nondeductible lobbying expenses, partially offset by research and development credits. For the three and six months ended June 30, 2025, we recognized a benefit from income taxes of $6.7 million and $4.9 million, respectively, representing an effective tax rate of 27.7% and 24.0%, respectively, which was higher than the 27 Table of Contents EHEALTH, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) statutory federal tax rate primarily due to state taxes, nondeductible stock-based compensation and lobbying expenses, partially offset by research and development credits and discrete adjustments. Assessing the realizability of our deferred tax assets is dependent upon several factors, including the likelihood and amount, if any, of future taxable income in relevant jurisdictions during the periods in which those temporary differences become deductible. We forecast taxable income by considering available positive and negative evidence, including our history of operating income and losses and our financial plans and estimates that we use to manage the business. These assumptions require significant judgment about future taxable income. As a result, the amount of deferred tax assets considered realizable is subject to adjustment in future periods if estimates of future taxable income change. We continue to recognize our deferred tax assets as of June 30, 2026, as we believe it is more likely than not that such deferred tax assets will be realized, with the exception of certain net operating losses and credits that are expected to expire unutilized which have a valuation allowance. 28 Table of Contents